Announcements

Afferent Medical Solutions, a UK-based bioelectronics medicine company developing novel device-based neuromodulation solutions for the treatment of circulatory system diseases and other therapeutic areas poorly served by existing medication, has successfully obtained from a Notified Body the ISO 13485 certification, marking a significant milestone in the company's commitment to excellence and adherence to rigorous quality standards

Afferent Medical Solutions announces a successful completion of its Phase II sham-controlled randomized trial, looking at autonomic modulation by transcutaneous vagal nerve stimulation in acute ischemic stroke patients requiring mechanical thrombectomy

Afferent Medical Solutions proudly unveils the receipt of a prestigious £650k RAIA award to run a Phase II clinical trial, focused on exploring the efficacy of TanX (Transcutaneous Autonomic Neuromodulation) in post-stroke recovery patients. This award will not only propel the research and development of tAN but will also facilitate the conceptualisation and subsequent development of a remote patient monitoring solution to complement the existing medical device treatment

Afferent Medical Solutions announces MHRA approval of SCRATCH-HTN Ph.II sham-controlled randomized control trial evaluating the safety, acceptability and efficacy of autonomic neuromodulation using trans-cutaneous auricular sensory stimulation in uncontrolled hypertensive patients

Afferent Medical Solutions announces the successful closure of its seed round funding, marking a pivotal milestone in its journey toward advancing novel, non-invasive, device-based medical solutions

Afferent Medical Solutions announces a £1.1 million i4i award to finance a Phase II Clinical (SCRATCH-HTN) confirmatory trial and to develop and CE mark its novel non-invasive device based solution. SCRATCH-HTN is a Sham controlled Randomized Control Trial evaluating the Safety, Acceptability and Efficacy of Autonomic neuromodulation using trans-cutaneous auricular sensory stimulation in uncontrolled hypertensive patients.

https://www.qmul.ac.uk/whri/research/scratch-htn/

Afferent Medical Solutions announces the successful completion of its in human Proof-of-Concept study demonstrating early indication of efficacy in reducing arterial blood pressure using its novel non-invasive device based solution